What question did this study set out to answer?

Identify independent predictors of long-term survival and disease-free outcomes in patients treated for Stage II appendicular osteogenic sarcoma.

February 1, 1992CancerOpen Access

Survival, prognosis, and therapeutic response in osteogenic sarcoma. The memorial hospital experience

View Full Paper

Ask AI

Bookmark

Why the study?

What are the predictors of long-term survival in patients with Stage II osteogenic sarcoma of the appendicular skeleton?

Population

279 consecutive patients with Stage II osteogenic sarcoma of the appendicular skeleton treated between 1976…

Design

Cohort

Follow-up

10 years

Authors

DGDale B. GlasserUniversity of Iowa JLJoseph M. LaneHospital for Special Surgery AHAndrew G. HuvosMemorial Sloan Kettering Cancer Center

Discussion

Member takes

Implication

Histologic response may aid prognostication in stage II osteogenic sarcoma; leaves open whether it should guide therapy intensification in trials.

Key Points

Identify independent predictors of long-term survival and disease-free outcomes in patients treated for Stage II appendicular osteogenic sarcoma.
Evaluated 279 consecutive patients (N=279) with Stage II osteogenic sarcoma of the appendicular skeleton treated between 1976 and 1986.
Conducted univariate and multivariate analyses to determine the prognostic significance of tumor location, local recurrence, and histologic response (tumor necrosis) following intravenous neoadjuvant chemotherapy.
Overall survival was 77% at 5 years and 73% at 10 years, with disease-free survival rates of 70% and 69%, respectively.
Incomplete histologic response to chemotherapy independently increased failure rates nearly fivefold compared to complete response (relative risk, 4.9; 95% CI, 2.2 to 11).
Local recurrence risk was elevated in tumors of the femur versus other sites (relative risk, 4.6) and proximal versus distal femur (relative risk, 3.4), but histologic response was the sole independent predictor after controlling for local recurrence.

Structured PICO

What are the predictors of long-term survival in patients with Stage II osteogenic sarcoma of the appendicular skeleton?

Population

279 consecutive patients with Stage II osteogenic sarcoma of the appendicular skeleton treated between 1976 and 1986

Intervention

Intravenous neoadjuvant chemotherapy and local control

Outcome

Long-term survival (overall and disease-free survival at 5 and 10 years)hard clinical

Histologic response to neoadjuvant chemotherapy is a strong independent predictor of long-term survival in patients with Stage II osteogenic sarcoma.

Cite This Study

Glasser et al. (1992) studied this question.

synapsesocial.com/papers/6a7c1f7148312d37e47606cf https://doi.org/10.1002/1097-0142(19920201)69:3<698::aid-cncr2820690317>3.0.co;2-g

View Full Paper

Ask AI

Bookmark

Implication

Histologic response may aid prognostication in stage II osteogenic sarcoma; leaves open whether it should guide therapy intensification in trials.

Survival, prognosis, and therapeutic response in osteogenic sarcoma. The memorial hospital experience

Discussion

Member takes

Implication

Key Points

Structured PICO

Cite This Study

Survival, prognosis, and therapeutic response in osteogenic sarcoma. The memorial hospital experience

Discussion

Member takes

Implication

Key Points

Structured PICO

Cite This Study

Also Consider

Also Consider